Anthony B El-Khoueiry1, Robert O'Donnell2, Thomas J Semrad2, Philip Mack2, Suzette Blanchard3, Nathan Bahary4, Yixing Jiang5, Yun Yen3, John Wright6, Helen Chen6, Heinz-Josef Lenz7, David R Gandara2. 1. University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3459, Los Angeles, CA, 90089, USA. elkhouei@med.usc.edu. 2. University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. 3. City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 4. University of Pittsburgh Comprehensive Cancer Center, Pittsburgh, PA, USA. 5. University of Maryland, Baltimore, MD, USA. 6. National Cancer Institute at the National Institutes of Health, Bethesda, MD, USA. 7. University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3459, Los Angeles, CA, 90089, USA.
Abstract
PURPOSE: The insulin-like growth factor (IGF) pathway is activated in hepatocarcinogenesis. Cixutumumab is a monoclonal antibody against human insulin-like growth factor-1 receptor (IGF-1R). Given the cross-talk between the IGF and VEGF pathways, we performed a phase I study of the combination of cixutumumab and sorafenib in hepatocellular cancer (HCC). METHODS: Eligible patients with no prior systemic therapy for advanced HCC and Child-Pugh A to B7 were treated with sorafenib 400 mg BID and escalating doses of cixutumumab (2, 4, or 6 mg/kg IV weekly) in a 3 + 3 design. Dose limiting toxicity (DLT) was defined as treatment-related grade 3 or 4 non-hematologic toxicity (except for a subset of manageable toxicities) or any grade 4 hematologic toxicities. RESULTS: In 21 patients enrolled, there were 3 DLTs; grade 3 hyperglycemia, grade 3 hypophosphatemia, and grade 5 peritonitis. The maximum tolerated dose of cixutumumab was 4 mg/kg IV weekly with standard dose sorafenib. Eighteen of 21 (86%) patients had grade 3 or above toxicities attributed to treatment. One patient also experienced grade 4 colonic perforation and grade 5 peritonitis. The median number of cycles completed was 4 (0-26). Of 16 patients evaluable for response, 81% achieved stable disease. The median progression free survival was 6.0 months (95% CI 3.6-undefined) and the median overall survival was 10.5 months (95% CI 7.1-undefined). CONCLUSIONS: While the combination of cixutumumab and sorafenib had a toxicity profile similar to that of sorafenib monotherapy, it manifested limited clinical efficacy in unselected patients with HCC.
PURPOSE: The insulin-like growth factor (IGF) pathway is activated in hepatocarcinogenesis. Cixutumumab is a monoclonal antibody against humaninsulin-like growth factor-1 receptor (IGF-1R). Given the cross-talk between the IGF and VEGF pathways, we performed a phase I study of the combination of cixutumumab and sorafenib in hepatocellular cancer (HCC). METHODS: Eligible patients with no prior systemic therapy for advanced HCC and Child-Pugh A to B7 were treated with sorafenib 400 mg BID and escalating doses of cixutumumab (2, 4, or 6 mg/kg IV weekly) in a 3 + 3 design. Dose limiting toxicity (DLT) was defined as treatment-related grade 3 or 4 non-hematologic toxicity (except for a subset of manageable toxicities) or any grade 4 hematologic toxicities. RESULTS: In 21 patients enrolled, there were 3 DLTs; grade 3 hyperglycemia, grade 3 hypophosphatemia, and grade 5 peritonitis. The maximum tolerated dose of cixutumumab was 4 mg/kg IV weekly with standard dose sorafenib. Eighteen of 21 (86%) patients had grade 3 or above toxicities attributed to treatment. One patient also experienced grade 4 colonic perforation and grade 5 peritonitis. The median number of cycles completed was 4 (0-26). Of 16 patients evaluable for response, 81% achieved stable disease. The median progression free survival was 6.0 months (95% CI 3.6-undefined) and the median overall survival was 10.5 months (95% CI 7.1-undefined). CONCLUSIONS: While the combination of cixutumumab and sorafenib had a toxicity profile similar to that of sorafenib monotherapy, it manifested limited clinical efficacy in unselected patients with HCC.
Authors: Todd W Bauer; Ray J Somcio; Fan Fan; Wenbiao Liu; Marjorie Johnson; Donald P Lesslie; Douglas B Evans; Gary E Gallick; Lee M Ellis Journal: Mol Cancer Ther Date: 2006-07 Impact factor: 6.261
Authors: R Granata; L Trovato; E Lupia; G Sala; F Settanni; G Camussi; R Ghidoni; E Ghigo Journal: J Thromb Haemost Date: 2007-02-09 Impact factor: 5.824
Authors: Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix Journal: N Engl J Med Date: 2008-07-24 Impact factor: 91.245
Authors: Julie A Price; Stephen J Kovach; Timothy Johnson; Leonidas G Koniaris; Paul A Cahill; James V Sitzmann; Iain H McKillop Journal: Hepatology Date: 2002-11 Impact factor: 17.425
Authors: Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang Journal: J Clin Oncol Date: 2014-12-29 Impact factor: 44.544